Status:
COMPLETED
Peri-operative Azithromycin to Improve Early Allograft Function and Outcome After Lung Transplantation
Lead Sponsor:
Universitaire Ziekenhuizen KU Leuven
Collaborating Sponsors:
Fund for Scientific Research, Flanders, Belgium
KU Leuven
Conditions:
Disorder Related to Lung Transplantation
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study investigates possible beneficial effects of peri-operative treatment (i.e. pre-transplant initiation and prompt post-transplant continuation) with azithromycin in lung transplantation. Our ...
Detailed Description
After a lung transplant recipient is put on the waiting list for subsequent lung transplantation, informed consent will be sought for the current study. If signed informed is obtained, the patient wil...
Eligibility Criteria
Inclusion
- Signed informed consent
- Adult (age at least 18 years old at moment of transplantation)
- Single lung transplantation, sequential single (double) lung transplantation or heart-lung transplantation
Exclusion
- Known previous allergy for azithromycin (including skin reactions such as rash, urticaria or Stevens- Johnson syndrome, angioneurotic oedema and anaphylaxis)
- Retransplantation or multi-organ (other than heart-lung) transplantation
- Inclusion in Transmedics® Organ Care System (OCS™ LUNG) study (OCS-LUN-03-2010)(S53795).
Key Trial Info
Start Date :
September 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT01915082
Start Date
September 1 2013
Last Update
November 11 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals Leuven
Leuven, Belgium, B-3000